Nitazoxanide \[2-acetolyloxy-*N*-(5-nitro-2-thiazolyl)benzamide, NTZ\] is a new anti-infective thiazolide used in the United States for treating Giardia- and Cryptosporidium-originated enteritis. We have recently shown that NTZ is effective in reducing clinical symptoms in hospitalized pediatric patients with severe rotavirus infection (Rossignol, J.F., et al., 2006. Lancet 368, 124--129). We now report that NTZ and its active circulating metabolite tizoxanide \[2-hydroxy-*N*-(5-nitro-2-thiazolyl)benzamide, TIZ\], have a broad-spectrum antiviral activity, effectively inhibiting the replication of several RNA and DNA viruses in experimental in vitro models. The thiazolides were found to be effective at low micromolar concentrations, which were non toxic to uninfected cells, against viruses belonging to seven different families including: simian SA11 and human Wa G1P1A rotaviruses, influenza A (PR8 and WSN strains) viruses, Sendai virus (SV), respiratory syncytial virus (RSV), coronavirus (CCoV), vesicular stomatitis virus (VSV), adenovirus (Ad5) and herpes simplex virus type 1 (HSV-1). IC~50~ and S.I. varied between 0.5 and 2 μg/ml and, 25 and \>100, respectively, in the different experimental models examined. In the case of rotavirus and paramyxovirus infection, both drugs were found to protect the host cell from the cytophatic effect caused by the virus for at least 24 h p.i. Approximately, 20 NTZ derivatives have now been tested for antiviral activity, some of which were found to be more effective than the parent compound. The mechanism of the antiviral activity was studied in cells infected with rotaviruses and influenza viruses. Thiazolides do not inhibit viral RNA transcription and do not cause a general block of virus protein synthesis, but act at post-translational level interfering with the correct processing of selected viral glycoproteins, thus hindering the formation of mature viral particles.
